Trial of Pembrolizumab for HIV-Positive Patients with Recurrent or Refractory Cancer
In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.
Media Type: Html
- SourceUrl: https://www.cancer.gov/publishedcontent/syndication/1050232.htm
- Syndication ID: 19862
- Language: English
- Source: National Cancer Institute (NCI)
- Date Syndication Captured: Monday, March 23, 2020 at 07:16 PM
- Date Syndication Updated: Tuesday, July 28, 2020 at 06:26 AM
Tags
General:
adult primary liver cancer
Embed Code Snippet
To get the embed code snippet please Login.
